This is What Merck & Co. (MRK) is Doing to Mitigate Against KEYTRUDA Exclusivity Loss

Merck & Co., Inc. (NYSE:MRK) is one of Goldman Sachs top healthcare stocks. On March 3 at the TD Cowen 46th Annual Health Care Conference, Merck & Co., Inc. (NYSE:MRK) unveiled strategic initiatives to mitigate the loss of exclusivity of its blockbuster drug, KEYTRUDA. The company expects a shallow dip in revenues from the flagship drug as its exclusivity ends.

This is What Merck & Co., Inc. (MRK) is Doing To Mitigate Against KEYTRUDA Exclusivity Loss

The strategic initiatives focus on innovation to transform the current portfolio through new products. The company is already expanding its oncology pipeline while also exploring new treatment options in cardiovascular and other therapeutic areas. Some of the new products slated for launch include WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX.

MK-1406 clinical trials for influenza prevention are ongoing in the Southern Hemisphere, while V940, a neoantigen therapy, is under development, with a melanoma readout expected in 2028. It is also working on MK-3000, which targets patients with diabetic macular edema and neovascular AMD.

Merck is also developing over 20 new growth drivers in the human health business as it targets $70 billion in commercial opportunity. The company is also pursuing strategic business development to double animal health revenue by mid-2030.

Merck & Co., Inc. (NYSE:MRK) is a leading, research-intensive global biopharmaceutical company that discovers, develops, and manufactures prescription medicines, vaccines, and biologic therapies. It specializes in human health—particularly oncology, infectious diseases, and immunology—while also providing animal health products.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.